These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 17186975)
1. Do valsartan and losartan have the same effects in the treatment of coronary artery disease? Iwata A; Miura S; Imaizumi S; Kiya Y; Nishikawa H; Zhang B; Shimomura H; Kumagai K; Matsuo K; Shirai K; Saku K Circ J; 2007 Jan; 71(1):32-8. PubMed ID: 17186975 [TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of valsartan on target lesion revascularization after percutaneous coronary interventions with bare-metal stents. Okada T; Yamamoto H; Okimoto T; Otsuka M; Ishibashi K; Dohi Y; Fujii T; Tadehara F; Kurisu S; Hayashi Y; Kihara Y; Circ J; 2011; 75(7):1641-8. PubMed ID: 21576829 [TBL] [Abstract][Full Text] [Related]
3. Comparison of efficacy of low- (80 mg/day) and high- (160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions. Peters S Am J Cardiovasc Drugs; 2008; 8(2):83-7. PubMed ID: 18422391 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340 [TBL] [Abstract][Full Text] [Related]
5. Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor. Yano H; Hibi K; Nozawa N; Ozaki H; Kusama I; Ebina T; Kosuge M; Tsukahara K; Okuda J; Morita S; Umemura S; Kimura K Circ J; 2012; 76(6):1442-51. PubMed ID: 22473458 [TBL] [Abstract][Full Text] [Related]
6. Valsartan versus ACE inhibition after bare metal stent implantation--results of the VALVACE trial. Peters S; Trümmel M; Meyners W; Koehler B; Westermann K Int J Cardiol; 2005 Feb; 98(2):331-5. PubMed ID: 15686787 [TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
8. Cardio-cerebrovascular protective effects of valsartan in high-risk hypertensive patients with coronary artery disease (from the Kyoto Heart Study). Shiraishi J; Sawada T; Koide M; Yamada H; Matsubara H; Am J Cardiol; 2012 May; 109(9):1308-14. PubMed ID: 22325086 [TBL] [Abstract][Full Text] [Related]
9. Late lumen loss and follow-up percent diameter stenosis at different doses of oral valsartan six months after bare-metal stent implantation in type B2/C coronary lesions. Peters S; Koehler B; Steffen H; Rählert-Sommer A; Selbig D; Trümmel M Int J Cardiol; 2010 Jun; 142(1):29-32. PubMed ID: 19419785 [TBL] [Abstract][Full Text] [Related]
10. [ARB II in chronic heart failure. Coincidences and divergences. Class effect?]. Barrios Alonso V; Escobar Cervantes C; Calderón Montero A Rev Clin Esp; 2005 Oct; 205(10):499-506. PubMed ID: 16238962 [TBL] [Abstract][Full Text] [Related]
11. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836 [TBL] [Abstract][Full Text] [Related]
12. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Smith DH; Dubiel R; Jones M Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537 [TBL] [Abstract][Full Text] [Related]
13. Angiotensin II receptor blockers for the treatment of heart failure: a class effect? Hudson M; Humphries K; Tu JV; Behlouli H; Sheppard R; Pilote L Pharmacotherapy; 2007 Apr; 27(4):526-34. PubMed ID: 17381379 [TBL] [Abstract][Full Text] [Related]
14. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Suzuki H; Kanno Y; Sugahara S; Ikeda N; Shoda J; Takenaka T; Inoue T; Araki R Am J Kidney Dis; 2008 Sep; 52(3):501-6. PubMed ID: 18653268 [TBL] [Abstract][Full Text] [Related]
15. Valsartan prevents neointimal hyperplasia after carotid artery stenting by suppressing endothelial cell injuries. Suzuki H; Sano T; Umeda Y; Yamamoto A; Toma N; Sakaida H; Taki W Neurol Res; 2015 Jan; 37(1):35-42. PubMed ID: 24938321 [TBL] [Abstract][Full Text] [Related]